Key result
Andexanet alfa was compared to 3- and 4-factor prothrombin complex concentrates for the reversal of rivaroxaban-induced anticoagulation and bleeding in a rabbit acute hemorrhage model.
Why the study?
Does andexanet alfa improve reversal of anticoagulation effects of rivaroxaban compared to 3- and 4-factor PCCs in a rabbit acute hemorrhage model?
Does andexanet alfa improve reversal of anticoagulation effects of rivaroxaban compared to 3- and 4-factor PCCs in a rabbit acute hemorrhage model?
Answers are grounded in this paper and cite their sources.
Wait, the key finding provided in the prompt is just "Andexanet alfa was compared.
The objective of these studies was to compare 3-and 4-factor PCCs, approved for reversal of warfarin, with and exanet alfa in reversing anticoagulation effects of rivaroxaban, a direct FXa inhibitor, in a rabbit model of bleeding.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2017) studied this question. Andexanet alfa was compared to 3- and 4-factor prothrombin complex concentrates for the reversal of rivaroxaban-induced anticoagulation and bleeding in a rabbit acute hemorrhage model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: